Faron Pharmaceuticals Oy · LSE:FARN
Faron Pharmaceuticals Oy — Investor Day (October 2024)
92 slides from Faron Pharmaceuticals Oy's investor day presentation, Oct 22, 2024
Slide 1: Activate your body to deactivate cancer
ACTIVATE YOUR BODY TO DEACTIVATE CANCER Faron's Capital Markets Day, 22 October 2024 1 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 2: Corporate Disclaimer
Corporate Disclaimer The contents of this presentation have not been approved by an authorized person within the meaning of Section 21 of the Financial Services and Markets Act 2000 (as amended) ("FSMA"). Reliance on the contents of this presentation for the purpose of engaging in any investment act
Slide 3: Today's agenda and presenters
Today’s agenda and presenters Faron’s role now and in the future in Establishing bexmarilimab as a cornerstone the development of bexmarilimab treatment for solid tumors Juho Jalkanen, CEO, Faron Petri Bono, CMO, Faron BEXMAB r/r MDS follow-up data on Who benefits from bexmarilimab and why? previous
Slide 4: Leadership focused on delivering value to patients and investors
Leadership focused on delivering value to patients and investors The key people working for you 24/7 Juho Jalkanen Maija Hollmén Yrjö Wichmann Petri Bono CEO CSO CFO CMO Turku, Finland 24 2007 Global Headquarters Employees Year Founded 4 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 5: What have we delivered in the past 6 months
What have we delivered in the past 6 months • We’ve raised > €30 million and become a financial healthy and well traded stock And you • We’ve continued to produce exceptional Phase 2 clinical results thought that we in r/r MDS and are on track to complete Phase 2 enrolment • We’ve obtained excellent
Slide 6: Faron's role now and in the future in the development of bexmarilimab
Faron’s role now and in the future in the development of bexmarilimab Juho Jalkanen CEO, Faron 6 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 7: Cancer
A leading cause of death CANCER 7 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 8: Treatment resistance
Why does cancer kill? TREATMENT RESISTANCE 8 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 9: Macrophages
A leading cause of treatment resistance MACROPHAGES 9 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 10: CLEVER-1
A master regulator of macrophages CLEVER-1 10 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 11: Bexmarilimab (Bex)
The best drug candidate for CLEVER-1 BEXMARILIMAB (BEX) 11 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 12: What do we aim to achieve?
What do we aim to achieve? Our purpose is to establish Bex as a cornerstone drug for cancer, in ALL indications where CLEVER-1 macrophages are a source of treatment resistance and cancer progression. 12 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 13: What does this mean?
What does this mean? This means possibly being able to help 20-30% of all cancer patients. 13 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 14: How do we aim to achieve this?
How do we aim to achieve this? 1. 2. 3. 4. Best achieved with Phase 3 studies Faron is ideally suited The more proof-of- a series of smart and are done in to accomplish this concept data Faron cost-effective Phase 2 partnership with with its knowhow, generates, the higher proof-of-concept (PoC) comm
Slide 15: Faron's strategy
Faron’s strategy A balance of de-risking the made investments and retaining future value of bexmarilimab Become revenue generating with data from MDS The next business • Partnership(s) and first approvals decisions we make Expand by generating PoC Phase 2 data in new indications • Both in blood canc
Slide 16: Q&A
Q&A 16 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 17: BEXMAB r/r MDS follow-up data on previously reported patients
BEXMAB r/r MDS follow-up data on previously reported patients Mika Kontro Principal Investigator of the BEXMAB trial, HUS 17 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 18: Prognosis of r/r MDS is poor
The prognosis of myelodysplastic syndrome (MDS) that has not responded or has relapsed on standard care (r/r MDS) is poor Large population of patients1) No viable treatment options for r/r MDS2) ~180-510K people globally live with MDS 50% of patients will not respond to hypometylating agent New diag
Slide 19: Bexmarilimab's mechanism of action to treat r/r MDS
Bexmarilimab’s (anti-CLEVER-1 mAb) mechanism of action to treat r/r MDS A novel dual mechanism of action that activates your cells to deactivate cancer ⚫ Bexmarilimab targets the CLEVER-1 receptor on immune cells (monocytes), 1 reprogramming them from an immune ⚫ Bexmarilimab deactivates the suppres
Slide 20: BEXMAB trial design
BEXMAB trial design 20 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 21: Study design: Phase I/II study with standard of care
BEXMAB Doublet Study design: Phase I/II Study Evaluating Bexmarilimab with Standard of Care Dose Finding (Phase I) Efficacy Evaluation (Phase II) POPULATION DOUBLET r/r MDS (n=32) Frontline HR MDS / CMML azacitidine r/r AML + bexmarilimab Phase 2 doses MDS / CMML failed HMA-based therapy 1st line MD
Slide 22: BEXMAB Study Sites
BEXMAB Study Sites Clinical Investigators (Finland) Clinical Investigators (US) Mika Kontro, MD/PhD (Associate Professor, Department Naval Daver, MD (Professor, Department of Leukemia, of Hematology, Helsinki University Hospital Division of Cancer Medicine, MDACC) Comprehensive Cancer Center, Helsin
Slide 23: BEXMAB Study Emerging Biomarker Data
BEXMAB Study Emerging Biomarker Data 23 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 24: Bexmarilimab increases antigen presentation and lymphocyte numbers in bone marrow
Bexmarilimab increases antigen presentation and lymphocyte numbers in the bone marrow 24 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 25: Biomarkers for patient selection and efficacy
Biomarkers for patient selection and efficacy 25 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 26: BEXMAB Study Emerging Safety and Efficacy Data
BEXMAB Study Emerging Safety and Efficacy Data 26 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 27: Bexmarilimab-related adverse events were rare and all Grade 1-2
Bexmarilimab-related adverse events were rare and all Grade 1-2 Data Cut-off Oct 4, 2024 • Only 4 bexmarilimab-related adverse events in 3 patients • Nausea (1), peripheral oedema, limb (1), pyrexia (1), infusion-related reaction (1) • All AEs of Grade 1 and 2; none of Grade 3-5 • These patients had
Slide 28: Positive r/r MDS results in on-going Phase 2 trial
Positive r/r MDS results in on-going Phase 2 trial May ’24 update Majority of responses are deep and durable1) * allo-HSCT 9 out of 14 r/r MDS patients have allo-HSCT achieved treatment response allowing two patients to undergo a Transformed into AML stem cell transplant1) Extended survival For
Slide 29: Positive survival results continue in Oct '24 update
Positive survival results continue in Oct ’24 update Median follow-up of r/r MDS patients increased (from 135 to 275 days) Majority of responses are still deep and durable1) 8 out of 14 achieved marrow responses (CR or mCR) Altogether 11 out of 14 r/r MDS patients have achieved treatment response
Slide 30: Long overall survival for BEXMAB r/r MDS patients
Long overall survival for BEXMAB r/r MDS patients, N=14 Overall Survival • Median OS 13.4 months (historical for r/r MDS 5-6 months) • Median time on bexmarilimab treatment for r/r MDS 7.9 months Days 30 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 31: Q&A
Q&A 31 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 32: Results of MDS Market Research
Results of MDS Market Research Ralph Hughes PharmaVentures 32 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 33: KOL and Payer Insights on Bexmarilimab
KOL and Payer Insights on Bexmarilimab October 2024
Slide 34: Disclaimer
| 34 Disclaimer This document has been prepared by the persons identified below and all information contained Actual events may vary from these interpretations, estimates and forecasts and you are in this document is current up to August 2024 or the date specified in the accompanying text. cautioned
Slide 35: Table of Contents
PAYER AND KOL INSIGHTS ON BEXMARILIMAB | 35 Table of Contents 01 PHARMAVENTURES 4 02 MARKET OVERVIEW 7 03 KOL INSIGHTS 11 04 PATIENT POPULATION 16 05 PAYER INSIGHTS 19
Slide 36: About PharmaVentures
ABOUT PHARMAVENTURES | OVERVIEW | 36 PharmaVentures is a leading life science and healthcare advisory firm providing business development & licensing, valuation, strategy and M&A services to clients around the world. Founded in 1992, we have completed over Industry Knowledge Profound Connections 100
Slide 37: PharmaVentures' Task
EXECUTIVE SUMMARY | 37 PharmaVenture’s Task Scope KOLs In this report, PharmaVentures assessed the market We engaged with 4 hematologists based in the US, PV were commissioned to review access landscape and pricing potential for Germany, and Spain. the TPP for Bexmarilimab with bexmarilimab with pay
Slide 38: Market Overview
| 38 Market Overview
Slide 39: Epidemiology based patient flow for MDS is highly complex
EPIDEMIOLOGY | 39 Epidemiology based patient flow for MDS is highly complex due to multiple lines of therapy and cannibalisation of second line by first line and anaemia status Patient Flow Dynamics The epidemiology model identifies incident patients only in US and 0.030‰* 0.026‰* 0.075‰* EU5. The t
Slide 40: GlobalData MDS Epidemiology
EPIDEMIOLOGY | 40 GlobalData® MDS Epidemiology ▪ PV’s patient-based model is dynamic i.e. in year and ▪ PharmaVentures used the GlobalData® report on MDS incident patients are being treated and moving from a 1L which is a patient-based analysis with data from primary setting to a 2L treatment. sourc
Slide 41: Generic HMAs are typically low-cost; expensive MDS drugs
BEACON - AFFORDABILITY | 41 Generic HMAs are typically low-cost. Expensive MDS drugs include oral medications and targeted therapies. Treatments for LR MDS, such as Rytelo and Reblozyl, also come with high monthly expenses. Category Intervention type US Price Anchors US Monthly Costs* EU Monthly cos
Slide 42: KOLs
| 42 Phare’
Slide 43: Most patients receive treatment but half fail to respond to 1st line
TREATMENT RATES | 43 Although most patients receive treatment, half fail to respond to 1st line treatment and most stop responding within 2 years. Therefore, improved response rates, duration of response and overall survival were seen as the biggest unmet needs in HR MDS “overall responses [to 1st l
Slide 44: KOLs on meeting the CR rates in the target product profile
TARGET PRODUCT PROFILE | 44 All KOLs agreed that meeting the CR rates in the TPP for bexmarilimab in both 1st line and r/r HR patients would represent a significant improvement on current SoC. “Those are very high numbers. It's very promising. The “the new standard of care will be the combination of
Slide 45: Bexmarilimab seen as most beneficial as 1st line in HR MDS
BEXMARILIMAB POSITIONING IN HR MDS | 45 Bexmarilimab was viewed as having most potential benefit as 1st line treatment in high risk MDS, where the majority of patients could be eligible, depending on comparison to venetoclax. KOLs expressed the opinion that although it may be easier to All KOLs ment
Slide 46: KOLs on bexmarilimab's mechanism of action
MECHANISM OF ACTION | 46 All KOLs agreed that bexmarilimab’s Mechanism of Action was encouraging and that immune modulation was a promising approach in MDS. The KOLs were not familiar with Clever-1 as a target and had Both US KOLs mentioned that although CD47 inhibitors have questions on selectively
Slide 47: Patient Population
| 47 Patient Population
Slide 48: Number of patients treated
PATIENT NUMBERS | 48 When high and low risk MDS in 1st and 2nd lines are combined, the number of patients treated by bexmarilimab peaks at just over 9,000 patients in the US alone in our projections ▪ The number of patients treated by bexmarilimab peaks at just ▪ The same situation can be observed w
Slide 49: Payers
1.49 Phare’
Slide 50: Bexmarilimab can be priced similarly to Rytelo in the US
PRICE | 50 Bexmarilimab can be priced similarly to Rytelo without significant hurdles in the US. However some more plans might look to reduce the price to a lower level through rebates. Prices $18k – $25k per month are realistic. In the US, oncology drugs are typically covered by insurers. However,
Slide 51: Detailed payer responses: prior authorisation
DETAILED PAYER RESPONSES | 51 Some health plans (2/4) may use prior authorisation (PA) as a utilization tool, but it is not always employed to restrict high-cost drugs. US #1 US #2 Prior authorization (PA) is required regardless of pricing to ensure proper diagnosis and appropriate The payer's healt
Slide 52: Most US payers cited Rytelo and Reblozyl as price benchmarks
DETAILED PAYER RESPONSES | 52 Most US payers (3/4) cited Rytelo and Reblozyl as good price benchmarks. Therefore, bexmarilimab can be priced similarly (~$25,000). Offering discounts (price at $18,000) could further reduce coverage hurdles. US #3 US #4 Regardless of pricing, the payer would cover bex
Slide 53: PharmaVentures contact details
One Kingdom Street Adrian Dawkes Stephen Waterman London W2 6BD Managing Director Managing Director United Kingdom adrian@pharmaventures.com stephen@pharmaventures.com +44 (0) 1865 332 700 www.pharmaventures.com Soren Demin Ralph Hughes Managing Director Senior Vice President soren@pharmaventures.co
Slide 54: Q&A
Q&A 54 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 55: Establishing bexmarilimab as a cornerstone treatment for solid tumors
Establishing bexmarilimab as a cornerstone treatment for solid tumors Petri Bono CMO, Faron 55 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 56: Immunotherapy as evolving cancer treatment option
Immunotherapy as evolving cancer treatment option FDA has approved 13 immune checkpoint inhibitors to treat 20 different cancer types 1) • While immune checkpoint inhibitors have advanced cancer immunotherapy, more effective and personalized treatments are still needed • Diversity, or heterogeneity,
Slide 57: Most patients do not derive benefit from current immunotherapies
Most patients do not derive benefit from current immunotherapies Expanding Scope of Immune Checkpoint Inhibitors • Primary resistance is common- immunotherapies do not work in tumors with low immune activity and T-cell infiltration. Pharmaceutical companies are looking for solutions for turning cold
Slide 58: Clever-1 targeting has profound effects on boosting cancer immunity
Clever-1 Targeting Has Profound Effects on Boosting Cancer Immunity Activation of the Innate as well as Adaptive Immune System Source: 1) Karikoski et al. Eur J Immunol 2009; Hollmen et al. Br J Cancer 2020 58 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 59: Clever-1 targeting has profound effects on boosting cancer immunity
Clever-1 Targeting Has Profound Effects on Boosting Cancer Immunity Activation of the Innate as well as Adaptive Immune System Source: 1) Karikoski et al. Eur J Immunol 2009; Hollmen et al. Br J Cancer 2020 59 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 60: Current bexmarilimab data in solid tumours
Current bexmarilimab Data in Solid Tumours 60 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 61: Proof of principle of modulating the tumor microenvironment
Proof of Principle of Modulating the Tumor Microenvironment (TME) Phase 1/2 First-in-Human MATINS Trial Highlights 216 patients treated across 10 different cancer types Targeting Clever-1 with bex is well tolerated, RP2D 1mg/kg Q3W supported by the FDA Bex converts intratumoral macrophages to suppor
Slide 62: MATINS updated safety and efficacy Part I and II
MATINS Updated Safety and Efficacy Part I and II Well tolerated therapy with clear clinical indications of efficacy and immune activation Treatment Related Adverse Events Patients (%) Confirmed Responses (RECIST) n (%) Any grade 94 (45) Complete response (CR) 0 (0) Grade 3 11 (5) Partial Response (P
Slide 63: More than 3 times longer survival for patients achieving disease control
More Than 3 Times Longer Survival for Patients Achieving Disease Control Attributed to bexmarilimab therapy Prior Therapy time to failure n=138 1.0 0.8 Survival (Probability) 0.6 0.4 0.2 0.0 no 115 74 31 18 8 3 2 1 1 yes 19 14 6 4 3 2 2 0 0 30 60 90 120 150 180 210 240 270 300 330 360 390 Days no ye
Slide 64: Patients with cold tumors responded to treatment
Patients With Cold Tumors Responded to Treatment As single agents bexmarilimab and anti-PD-1s benefit opposite melanoma populations Patients n (%) median % p- achieving disease (range) value control have Clever-1 78 (100) significantly lower Whole tumor 78 (100) 15 (1-55) levels of pro- inflammatory
Slide 65: Bexmarilimab – a drug for the IFN gamma low population
Bexmarilimab – a drug for the IFN gamma low population Bex treated melanoma patients according to IFN As single agents bexmarilimab and anti-PD-1s benefit opposite melanoma populations gamma status3 Anti-PD1 treated melanoma patients according to IFN gamma status1,2 Faron’s bexmarilimab aims to ta
Slide 66: Bexmarilimab solid tumors pipeline
Bexmarilimab Solid Tumors Pipeline 66 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 67: Faron Solid Tumours
Faron Solid Tumours Treatment Indication(s) Phase of Development Anticipated Key Milestones Preclinical Phase 1 Phase 2 Phase 3 Single-Agent Advanced solid tumors ▪ Completed Bexmarilimab FARON SPONSORED MATINS (First in Human, single agent) Bexmarilimab PD-1 Blockade Basket ▪ First-patient-in expec
Slide 68: BLAZE: Investigator Initiated
BLAZE: Investigator Initiated Can bexmarilimab overcome PD-1 resistance? • Resistance to first-line immunotherapy in 2025 2026 2027 NSCLC and melanoma is very common. H1 H2 H1 H2 H1 H2 Targeting of tumour associated macrophages may overcome resistance. Phase 2 • Response to bexmarilimab + anti-PD-1
Slide 69: BEXAR: Investigator Initiated
BEXAR: Investigator Initiated Can we turn cold tumors hot in soft-tissue sarcomas? • Early experiences with immune 2025 2026 2027 checkpoint inhibitors (ICIs) in clinical soft H1 H2 H1 H2 H1 H2 tissue sarcoma (STS) trials have been disappointing so far • These tumors are commonly regarded as Complet
Slide 70: MATINS-02: Faron sponsored basket trial in solid tumors
MATINS-02: Faron Sponsored basket trial in solid tumors Can bexmarilimab overcome PD-1 2025 2026 2027 resistance? H1 H2 H1 H2 H1 H2 • Results with PD-1 inhibitors have been disappointing in immunologically cold Phase 2 – Gastric Expansion tumors (such as gastric, ER+ breast Phase 1 (2nd line Gastric
Slide 71: Clever-1 highly expressed by malignant cells in AML, MDS and lymphomas
Clever-1 is highly expressed by malignant cells in AML, MDS, and also lymphomas B-ALL BCL/TCL Clever-1 is also expressed in B-cell T- and T-cell lymphomas- can we ALL MM MDS CML increase the efficacy of SoC agents AML or sensitize after failure? FAB AML M3 85-90% of non-Hodgkin lymphomas T-Lymphoid
Slide 72: Our bexmarilimab solid tumor mission
Our bexmarilimab solid tumor mission A Unique Approach to Fight Cancer via Re-programming Macrophages and Myeloid Cells Our purpose is to establish bexmarilimab as a cornerstone drug for cancer in indications where Clever-1 macrophages are a source of treatment resistance and cancer progression Bexm
Slide 73: Scientific Advisory Board further depth and experience
Scientific Advisory Board further depth and experience Scientific Advisors Toni Choueiri, MD, FASCO Naval G. Daver, MD Professor Professor Harvard, USA MD Anderson, CCC Tom Powles, MBBS, MRCP, MD Mika Kontro, MD, PhD Professor Adjunct Professor Barts Cancer Center, London HUS, CCC Amer Zeidan, MD, M
Slide 74: Scientific Advisory Board
Scientific Advisory Board Toni Choueiri, MD, FASCO Toni Choueiri1), MD is the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School, Boston, MA, the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute and co-leader of the Kidney C
Slide 75: Scientific Advisory Board
Scientific Advisory Board Tom Powles, MBBS, MRCP, MD Tom Powles, MBBS, MRCP, MD is a professor of urology cancer at the University of London and the Director of Barts Cancer Centre which is one of the UKs largest Cancer Centres. Prof Powles is also editor-in-chief of Annals of Oncology, the leading
Slide 76: Scientific Advisory Board
Scientific Advisory Board Amer Zeidan, MD, MBBS, MHS Amer Zeidan, MD, MBBS, MHS is a Associate Professor of Medicine, Chief of Hematologic Malignancies Division, Director of Hematology Early Therapeutics Research, and leader of the clinical program and the Clinical Research Team for Leukemia and Mye
Slide 77: Scientific Advisory Board
Scientific Advisory Board Naval G. Daver, MD Naval G. Daver, MD is a Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center (MDACC) in Houston, TX. He is a clinical investigator with a focus on molecular and immune therapies in acu
Slide 78: Scientific Advisory Board
Scientific Advisory Board Mika Kontro, MD, PhD Mika Kontro, MD, PhD is an adjunct professor and a consultant in clinical hematology at the Helsinki University Hospital Comprehensive Cancer Center. Dr. Mika currently works as K. Albin Johannson Cancer Research Fellow (Finnish Cancer Institute) and as
Slide 79: Scientific Advisory Board
Scientific Advisory Board Christophe Massard, MD, PhD Christophe Massard, MD, PhD is professor and a Head of Cancer Research at Gustave-Roussy, the first leading cancer hospital in Europe and in the top five of the world. Eugène Marquis Cancer Centre in Rennes, France. Dr. Christophe is a member of
Slide 80: Q&A
Q&A 80 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 81: Who benefits from bexmarilimab and why?
Who benefits from bexmarilimab and why? Maija Hollmén CSO, Faron 81 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 82: Timeline of clinically evaluated macrophage-reprogramming therapeutics
Timeline of clinically evaluated macrophage- reprogramming therapeutics Problems: overlapping strategies, safety issues, low efficacy as monotherapy Rannikko and Hollmén, BJC 2024 82 22-OCT-2024 FARON'S CAPITAL MARKETS DAY MATINS BEXMAB
Slide 83: Diversity of tumor-associated macrophages (TAM)
Diversity of tumor-associated macrophages (TAM) Finding the right population to target within heterogenous populations across tumors TNBC ER+ In vitro 83 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 84: Bexmarilimab activates TAMs in interferon-poor microenvironments
Bexmarilimab activates TAMs to support adaptive immune responses in interferon-poor immune microenvironments Rannikko et al., CIR 2024 84 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 85: The majority of cancers do not respond to immune checkpoint inhibition
The majority of cancers do not respond to immune checkpoint inhibition Overcoming resistance with bexmarilimab * * * * * Hirsch et al., BJC 2019 85 22-OCT-2024 FARON'S CAPITAL MARKETS DAY Syn et al., Lancet 2017 *
Slide 86: Potential of bexmarilimab use in immunologically cold tumors
Potential of bexmarilimab use in immunologically cold tumors Rethinking of immune phenotype rather than organ of origin as an indication C2 Clever-1 C4 Clever-1 low high P=0.09 P<0.001 Days Days Thorsson et al., Immunity 2018 86 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 87: Solving the problems of macrophage-targeted therapies
Solving the problems of macrophage-targeted therapies Patient selection is as important as knowing your drug, who to treat and when? • Overlapping strategies: Targeting Clever-1 with bexmarilimab is a novel approach and presents a completely new way of re-programming macrophages • Safety issues: Bex
Slide 88: Closing remarks
Closing remarks Juho Jalkanen CEO, Faron 88 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 89: Outlook
Outlook Potential to become cornerstone in cancer treatment Indication Patients Market size* (8MM) 2024 2030 Sarcoma 85 801 0.20 1.5 DLBCL and TCL 125 903 5.652 12.088 ER+/HER- 789 367 24.29 41.748 NSCLC 1 523 899 35.84 59.86 Melanoma 214 301 9.38 12.91 Gastric/stomach 240 350 1.66 4.01 Source: Eval
Slide 90: Outlook
Outlook Value creation opportunity with full Phase 2 read-outs (response rate, duration of response and survival), regulatory interactions, partnering and combination data with anti-PD-1 Outlook Faron as an investment opportunity Dec 2024 Phase II Interim readout at ASH Clear market opportunity with
Slide 91: Q&A session
Q&A session 91 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Slide 92: Thank You.
Thank You. 92 22-OCT-2024 FARON'S CAPITAL MARKETS DAY
Faron Pharmaceuticals Oy — Investor Day (October 2024) on 6ix